Aav8-rpgr (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 90 | 網膜色素変性症 | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003104-42-GB (EUCTR) | 26/06/2018 | 06/02/2018 | A long-term follow-up study to evaluate the safety and efficacy of retinal gene therapy in subjects with Choroideremia previously treated with AAV2-REP1 in an antecedent study and in subjects with X-Linked Retinitis Pigmentosa previously treated with AAV8-RPGR in an antecedent study | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study - SOLSTICE | Choroideremia (CHM)X-Linked Retinitis Pigmentosa (XLRP) MedDRA version: 20.1;Level: LLT;Classification code 10008791;Term: Choroideremia;System Organ Class: 100000004853 MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: AAV2-REP1 Product Code: AAV2-REP1 INN or Proposed INN: timrepigene emparvovec Other descriptive name: AAV2-REP1 Product Name: AAV8-RPGR Product Code: AAV8-RPGR Other descriptive name: AAV8-RPGR | NightstaRx Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 440 | Phase 3 | France;United States;Canada;Finland;Denmark;Netherlands;Germany;United Kingdom | ||
| 2 | NCT03116113 (ClinicalTrials.gov) | March 16, 2017 | 29/3/2017 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa | A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) | X-Linked Retinitis Pigmentosa | Biological: AAV8-RPGR | NightstaRx Ltd, a Biogen Company | NULL | Recruiting | 10 Years | N/A | Male | 63 | Phase 2;Phase 3 | United States;United Kingdom |
| 3 | EUCTR2016-003852-60-GB (EUCTR) | 09/01/2017 | 09/11/2016 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa using AAV8 | A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) - XIRIUS Study | X-Linked retinitis pigmentosa (XLRP) MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: AAV8-RPGR Product Code: AAV8-RPGR Other descriptive name: AAV8-RPGR | NightstaRx Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 63 | Phase 1;Phase 2;Phase 3 | United States;United Kingdom |